Latest Reimbursement News

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Nova Eye Medical Limited reported a 25% increase in revenue to AUD 29.3 million for FY2025, driven by strong sales in its glaucoma surgical devices segment, yet posted a net loss after tax of AUD 9.1 million. The company raised AUD 6.2 million through a share placement to support growth initiatives.

Worley Limited reported a robust FY25 with a 29% rise in statutory NPATA to $475 million and announced a $500 million share buy-back, underpinned by strong bookings and strategic cost management. The company anticipates moderate growth in FY26 despite ongoing geopolitical uncertainties.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Iondrive Ltd reported a 94.7% surge in revenue to $1.71 million for FY2025, driven by R&D tax incentives and other income, yet still recorded a net loss of $4.62 million amid high expenses. The company also expanded its footprint in Europe by acquiring a German entity.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.

Beacon Minerals has exercised its option to acquire the historic Wealth of Nations gold tenements, confirming high-grade mineralisation through an 11-hole drill program and setting the stage for a maiden resource estimate in 2026.

Nex Metals Explorations has partnered with the Wangkatja Tjungula Aboriginal Corporation to reprocess historic gold tailings at Kookynie, sharing profits and embedding cultural stewardship in rehabilitation efforts.

Sierra Nevada Gold (ASX – SNX) has qualified to bid for exploration licenses in Saudi Arabia’s Arabian Shield, leveraging its regional expertise to tap into a promising new frontier aligned with the Kingdom’s Vision 2030.

Medical Developments International reports a strong FY25 with significant margin gains and strategic progress, setting the stage for accelerated Penthrox expansion in FY26.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.